136
Participants
Start Date
April 16, 2010
Primary Completion Date
March 21, 2019
Study Completion Date
March 21, 2019
MEDI-551
MEDI-551 will be administered intravenously (IV) once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
Rituximab
Rituximab will be administered IV on Days 1, 8, 15, and 22 (28- day cycle). The treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches complete response or withdraws consent.
Research Site, Leuven
Research Site, Yvoir
Research Site, Ghent
Research Site, Lake Success
Research Site, Hershey
Research Site, Washington D.C.
Research Site, Morgantown
Research Site, Madrid
Research Site, Madrid
Research Site, Tampa
Research Site, Birmingham
Research Site, Modena
Research Site, Cona
Research Site, Milwaukee
Research Site, Rochester
Research Site, Chicago
Research Site, Westwood
Research Site, Houston
Research Site, La Jolla
Research Site, New Brunswick
Research Site, Montreal
Lead Sponsor
MedImmune LLC
INDUSTRY